Design Therapeutics Q2 EPS $(0.21) Beats $(0.23) Estimate
Benzinga Newsdesk 2 years ago
EarningsNews
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 41.67 percent increase over losses of $(0.36) per share from
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 41.67 percent increase over losses of $(0.36) per share from the same period last year.